Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Lemery

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2016
Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical StudyKun He, Huanyu Chen, Thomas Gwise, et al.
Dermatology Online Journal|June 7, 2022
Impact of an evolving regulatory landscape on skin cancer drug development in the U.SDavid M Miller, Sophia Z Shalhout, Denise Casey, et al.
British Journal of Haematology|January 18, 2006
Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndromeJamie Robyn, Steven Lemery, J Philip McCoy, et al.
The Oncologist|April 10, 2020
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell CarcinomaDiana Bradford, Suzanne Demko, Susan Jin, et al.
The Oncologist|February 2, 2018
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on SorafenibLorraine Pelosof, Steven Lemery, Sandra Casak, et al.
The Oncologist|May 11, 2021
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with SorafenibMay Tun Saung, Lorraine Pelosof, Sandra Casak, et al.
Blood|August 22, 2007
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingAmy D Klion, Jamie Robyn, Irina Maric, et al.
The Oncologist|December 21, 2020
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based ChemotherapyLorraine Pelosof, May Tun Saung, Martha Donoghue, et al.
JHEP Reports : Innovation in Hepatology|May 17, 2023
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinomaDavid J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.
JAMA Oncology|December 29, 2022
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2016
Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical StudyKun He, Huanyu Chen, Thomas Gwise, et al.
Dermatology Online Journal|June 7, 2022
Impact of an evolving regulatory landscape on skin cancer drug development in the U.SDavid M Miller, Sophia Z Shalhout, Denise Casey, et al.
British Journal of Haematology|January 18, 2006
Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndromeJamie Robyn, Steven Lemery, J Philip McCoy, et al.
The Oncologist|April 10, 2020
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell CarcinomaDiana Bradford, Suzanne Demko, Susan Jin, et al.
The Oncologist|February 2, 2018
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on SorafenibLorraine Pelosof, Steven Lemery, Sandra Casak, et al.
The Oncologist|May 11, 2021
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with SorafenibMay Tun Saung, Lorraine Pelosof, Sandra Casak, et al.
Blood|August 22, 2007
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingAmy D Klion, Jamie Robyn, Irina Maric, et al.
The Oncologist|December 21, 2020
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based ChemotherapyLorraine Pelosof, May Tun Saung, Martha Donoghue, et al.
JHEP Reports : Innovation in Hepatology|May 17, 2023
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinomaDavid J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.
JAMA Oncology|December 29, 2022
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, et al.
Pageof 3